A severe 2017 influenza season dominated by influenza A(H3N2), Victoria, Australia
DOI:
https://doi.org/10.5365/wpsar.2018.9.5.010Abstract
Surveillance for influenza-like illness (ILI) and laboratory-confirmed influenza in Victoria, Australia is undertaken jointly by the Victorian Infectious Diseases Reference Laboratory and the Victorian Government Department of Health and Human Services from May to October each year. Surveillance data comprise notifiable laboratory-confirmed influenza and ILI reporting from from two sources – a general practice sentinel surveillance programme and a locum service.
The magnitude of the 2017 influenza season was high in Victoria with widespread circulation of influenza type A(H3N2), which peaked in September. A record number of laboratory-confirmed influenza cases were notified, and the proportion of ILI cases to total consultations from both the general practice and locum service were higher than previous years. Notified cases of influenza A were older than influenza B cases with 25% compared to 17% aged more than 65 years, respectively. The proportion of swabs that were positive for influenza peaked at 58%. Antigenic characterization suggested a good match between the circulating and vaccine strains of influenza A(H3N2).
Most of the increases observed in notified cases of laboratory-confirmed influenza in recent years in Victoria have been attributed to increases in testing. However, that cases of ILI also increased in Victoria in 2017 is suggestive that 2017 was a relatively severe season. The dominance of influenza type A(H3N2), the extended duration of elevated activity, and a potential phylogenetic mismatch of vaccine to circulating strains are likely to have contributed to the relative severity of the 2017 season.
Victoria is Australia’s second most populous state and is the mainland’s southernmost state. It has a temperate climate with an influenza season usually occurring in the cooler months between May and October. The Victorian Infectious Diseases Reference Laboratory (VIDRL), in partnership with the Victorian Government Department of Health and Human Services (DHHS), coordinates influenza-like illness (ILI) and laboratory-confirmed influenza surveillance in Victoria. There are three data sources included in the influenza surveillance system.
References
Australian Government Department of Health. The Australian Immunisation Handbook. http://wwwimmunisehealthgovau/internet/immunise/publishingnsf/Content/Handbook10-home~handbook10part4~handbook10-4-7. 2017;10th Edition.
Druce JD, Tran T, Kelly H, Kaye M, Chibo D, Kostecki R, et al. Laboratory diagnosis and surveillance of human respiratory viruses by PCR in Victoria, Australia, 2002-2003. Journal of Medical Virology. 2005;75:122-9.
National Home Doctor Service. https://homedoctorcomau/. 2018.
Fielding JE, Levy A, Chilver MB, Deng YM, Regan AK, Grant KA, et al. Effectiveness of seasonal influenza vaccine in Australia, 2015: An epidemiological, antigenic and phylogenetic assessment. Vaccine. 2016 Sep 22;34(41):4905-12. PubMed PMID: 27577556.
Kelly HA, Grant KA, Tay EL, Franklin L, Hurt AC. The significance of increased influenza notifications during spring and summer of 2010-11 in Australia. Influenza and other respiratory viruses. 2013 Nov;7(6):1136-41. PubMed PMID: 23176174. Pubmed Central PMCID: 4634258.
Fielding JE, Regan AK, Dalton CB, Chilver MB, Sullivan SG. How severe was the 2015 influenza season in Australia? The Medical journal of Australia. 2016 Feb 1;204(2):60-1. PubMed PMID: 26821099.
Australian Government Department of Health. Australian Influenza Surveillance Report. http://wwwhealthgovau/internet/main/publishingnsf/Content/cda-ozflu-2017htm. 2017;No. 12, 2017.
Australian Government Department of Health. National Notifiable Diseases Surveillance System. http://www9healthgovau/cda/source/rpt_3cfm. 2017.
Institute of Environmental Science & Research Limited. Community and Hospital Surveillance, ILI, SARI, Influenza and Respiratory Pathogens. https://survesrcrinz/PDF_surveillance/Virology/FluWeekRpt/2017/MoH_Influenza_Report/FluWeekRpt201739pdf. 2017;2017 Influenza Season, Week 39, ending 1 October 2017.
PathWest. Virus WAtch. http://ww2healthwagovau/~/media/Files/Corporate/general%20documents/Infectious%20diseases/PDF/VWAtch/20171217_virus_watchpdf. 2017;WEEK ENDING 17TH DECEMBER 2017.
Centers for Disease Control and Prevention. FluView. https://wwwcdcgov/flu/weekly/. 2017;2017-2018 Influenza Season Week 12 ending March 24, 2018.
Government of Canada. FluWatch https://wwwcanadaca/en/public-health/services/publications/diseases-conditions/fluwatch/2017-2018/week12-march-18-march-24-2018html. 2018;March 18 to March 24, 2018 (week 12).
Kelly H, Grant K. Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2009 Aug 6;14(31). PubMed PMID: 19660248.
McCallum L, Partridge J. Epidemiological characteristics of the influenza A(H1N1) 2009 pandemic in the Western Pacific Region. Western Pacific surveillance and response journal : WPSAR. 2010 Oct;1(1):5-11. PubMed PMID: 23908874. Pubmed Central PMCID: 3729049.
World Health Organization. Recommended composition of influenza virus vaccines for use in the 2017 southern hemisphere influenza season. http://wwwwhoint/influenza/vaccines/virus/recommendations/2017_south/en/. 2017.
Sullivan SG, Chilver MB, Carville KS, Deng YM, Grant KA, Higgins G, et al. Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2017 Oct;22(43). PubMed PMID: 29090681. Pubmed Central PMCID: 5718387.
Skowronski DM, Chambers C, De Serres G, Dickinson JA, Winter AL, Hickman R, et al. Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2018 Feb;23(5). PubMed PMID: 29409570. Pubmed Central PMCID: 5801641.
Flannery B, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, et al. Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018. MMWR Morbidity and mortality weekly report. 2018 Feb 16;67(6):180-5. PubMed PMID: 29447141. Pubmed Central PMCID: 5815489.
Rondy M, Kissling E, Emborg HD, Gherasim A, Pebody R, Trebbien R, et al. Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2018 Mar;23(9). PubMed PMID: 29510782. Pubmed Central PMCID: 5840921.
The Australian Technical Advisory Group on Immunisation. ATAGI advice on seasonal influenza vaccines in 2018. https://betahealthgovau/resources/publications/atagi-advice-on-seasonal-influenza-vaccines-in-2018. 2018;21 March 2018.
Health M. FluCAN (The Influenza Complications Alert Network). http://wwwmonashhealthorg/page/A_Rapid_Alert_System_for_Severe_Respiratory_Illness_The_FluCAN_Surveillance_system. 2018.
